Suppr
超能文献

Sipuleucel-T.

作者信息

Higano Celestia S, Small Eric J, Schellhammer Paul, Yasothan Uma, Gubernick Steven, Kirkpatrick Peter, Kantoff Philip W

出版信息

Nat Rev Drug Discov. 2010 Jul;9(7):513-4. doi: 10.1038/nrd3220.

DOI:10.1038/nrd3220

PMID:20592741

Abstract

摘要

相似文献

Sipuleucel-T.

Nat Rev Drug Discov. 2010 Jul;9(7):513-4. doi: 10.1038/nrd3220.

How does sipuleucel-T alter our clinical practice?

BJU Int. 2010 Oct;106(7):945-6. doi: 10.1111/j.1464-410x.2010.09642.x.

Sipuleucel-T for the treatment of advanced prostate cancer.

Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N Engl J Med. 2010 Nov 11;363(20):1966; author reply 1967-8. doi: 10.1056/NEJMc1009982.

Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.

BioDrugs. 2011 Aug 1;25(4):255-6. doi: 10.2165/11207140-000000000-00000.

New drugs: Sipuleucel-T, cabazitaxel, and collagenase clostridium histolyticum.

J Am Pharm Assoc (2003). 2010 Nov-Dec;50(6):772-5. doi: 10.1331/JAPhA.2010.10542.

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.

Nat Rev Cancer. 2011 Oct 24;11(11):805-12. doi: 10.1038/nrc3153.

Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.

Oncology (Williston Park). 2011 Mar;25(3):261-2.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982.

Sipuleucel-T: When and for Whom to Recommend It.

Oncology (Williston Park). 2017 Dec 15;31(12):900-1, 910-2.

引用本文的文献

Synergistic targeting strategies for prostate cancer.

Nat Rev Urol. 2025 May 20. doi: 10.1038/s41585-025-01042-6.

Trial watch: anticancer vaccination with dendritic cells.

Oncoimmunology. 2024 Oct 9;13(1):2412876. doi: 10.1080/2162402X.2024.2412876. eCollection 2024.

Cracking the Codes behind Cancer Cells' Immune Evasion.

Int J Mol Sci. 2024 Aug 15;25(16):8899. doi: 10.3390/ijms25168899.

Feasibility Study for the Use of Gene Electrotransfer and Cell Electrofusion as a Single-Step Technique for the Generation of Activated Cancer Cell Vaccines.

J Membr Biol. 2024 Dec;257(5-6):377-389. doi: 10.1007/s00232-024-00320-5. Epub 2024 Aug 12.

Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives.

Comput Struct Biotechnol J. 2024 Apr 21;23:1833-1843. doi: 10.1016/j.csbj.2024.04.054. eCollection 2024 Dec.

Identification of gut microbes-related molecular subtypes and their biomarkers in colorectal cancer.

Aging (Albany NY). 2024 Jan 29;16(3):2249-2272. doi: 10.18632/aging.205480.

Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.

Exp Mol Med. 2023 Nov;55(11):2308-2319. doi: 10.1038/s12276-023-01114-w. Epub 2023 Nov 1.

Research progress of nanovaccine in anti-tumor immunotherapy.

Front Oncol. 2023 Aug 24;13:1211262. doi: 10.3389/fonc.2023.1211262. eCollection 2023.

Potency Assay Development: A Keystone for Clinical Use.

Adv Exp Med Biol. 2023;1420:13-28. doi: 10.1007/978-3-031-30040-0_2.

Responsive Microneedles as a New Platform for Precision Immunotherapy.

Pharmaceutics. 2023 May 4;15(5):1407. doi: 10.3390/pharmaceutics15051407.

本文引用的文献

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.

Cancer statistics, 2009.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.

Nat Clin Pract Oncol. 2008 Sep;5(9):506-7. doi: 10.1038/ncponc1201. Epub 2008 Jul 22.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Ann Pharmacother. 2008 Jan;42(1):91-8. doi: 10.1345/aph.1K429. Epub 2007 Dec 19.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

J Clin Oncol. 2006 Jul 1;24(19):3089-94. doi: 10.1200/JCO.2005.04.5252.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.

The promise of cancer vaccines.

Nat Rev Cancer. 2004 May;4(5):401-11. doi: 10.1038/nrc1359.

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

J Clin Oncol. 2000 Dec 1;18(23):3894-903. doi: 10.1200/JCO.2000.18.23.3894.

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Clin Cancer Res. 2000 Jun;6(6):2175-82.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Sipuleucel-T.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译